TY - JOUR T1 - Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network JF - Journal of Medical Genetics JO - J Med Genet DO - 10.1136/jmedgenet-2019-106759 SP - jmedgenet-2019-106759 AU - Alice Garrett AU - Alison Callaway AU - Miranda Durkie AU - Cankut Cubuk AU - Mary Alikian AU - George J Burghel AU - Rachel Robinson AU - Louise Izatt AU - Sabrina Talukdar AU - Lucy Side AU - Treena Cranston AU - Sheila Palmer-Smith AU - Diana Baralle AU - Ian R Berry AU - James Drummond AU - Andrew J Wallace AU - Gail Norbury AU - Diana M Eccles AU - Sian Ellard AU - Fiona Lalloo AU - D Gareth Evans AU - Emma Woodward AU - Marc Tischkowitz AU - Helen Hanson AU - Clare Turnbull A2 - , Y1 - 2020/03/13 UR - http://jmg.bmj.com/content/early/2020/03/13/jmedgenet-2019-106759.abstract N2 - Advances in technology have led to a massive expansion in the capacity for genomic analysis, with a commensurate fall in costs. The clinical indications for genomic testing have evolved markedly; the volume of clinical sequencing has increased dramatically; and the range of clinical professionals involved in the process has broadened. There is general acceptance that our early dichotomous paradigms of variants being pathogenic–high risk and benign–no risk are overly simplistic. There is increasing recognition that the clinical interpretation of genomic data requires significant expertise in disease–gene-variant associations specific to each disease area. Inaccurate interpretation can lead to clinical mismanagement, inconsistent information within families and misdirection of resources. It is for this reason that ‘national subspecialist multidisciplinary meetings’ (MDMs) for genomic interpretation have been articulated as key for the new NHS Genomic Medicine Service, of which Cancer Variant Interpretation Group UK (CanVIG-UK) is an early exemplar. CanVIG-UK was established in 2017 and now has >100 UK members, including at least one clinical diagnostic scientist and one clinical cancer geneticist from each of the 25 regional molecular genetics laboratories of the UK and Ireland. Through CanVIG-UK, we have established national consensus around variant interpretation for cancer susceptibility genes via monthly national teleconferenced MDMs and collaborative data sharing using a secure online portal. We describe here the activities of CanVIG-UK, including exemplar outputs and feedback from the membership. ER -